MedTrace Logo

Testing a Brief Reassurance Message Before a Musculoskeletal Clinic Visit

NCT07330492 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-01-09

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if a brief, reassuring pre-visit message affects patients' expectations and planned follow-up care in adults with common musculoskeletal conditions. The main questions it aims to answer are:

* Does reading a brief reassurance message before a clinic visit change how interested patients are in additional care, such as follow-up visits, tests, injections, or surgery?
* Does the message affect whether patients actually schedule follow-up care after the visit?

Researchers will compare participants who receive the pre-visit reassurance message to those who receive usual care to see if the message changes patients' enthusiasm for care or their follow-up decisions.

Participants will:

1. Read a short, easy-to-understand message about musculoskeletal symptoms and options for care (for those in the intervention group)
2. Complete a brief questionnaire rating their interest in follow-up visits, tests, injections, or surgery
3. Have their scheduled follow-up care recorded after the clinic visit

Conditions

  • Any Non-traumatic Musculoskeletal Condition

Interventions

BEHAVIORAL

Nudge intervention

The intervention involves reading a brief, easy-to-understand message prior to a musculoskeletal clinic visit. The message explains that many musculoskeletal symptoms are common, often related to normal age-related changes, and can improve with simple self-care. It emphasizes that visits, tests, injections, and treatments are often optional, and patients can choose how much care to pursue.

Sponsors & Collaborators

  • University of Texas at Austin

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-03-31
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07330492 on ClinicalTrials.gov